JDRF: Patient Needs Must Drive T1 Diabetes Innovation - schofieldcolooter

JDRF is an organization founded and driven by individuals directly adjoining to case 1 diabetes (T1D). Working to improve the lives of those affected by this disease as we create a world without T1D is what we're all almost — it's part of our DNA! The great unwashe brushed by T1D support JDRF because they trust that the inquiry we're driving volition make a divergence in their lives.

Because understanding the personal perspective of T1D is so important to JDRF, I was excited to be part of the DiabetesMine Innovation Summit this yr. This meeting place is a great opportunity for bringing the many T1D stakeholders, including those who have T1D, conjointly to talk over the issues that flat impact them. Here's my take on some of the significant voices I heard at the Peak this twelvemonth who are functional unitedly to change the lives of all those affected by T1D:

* Dr. Courtney Lias, with the US FDA (FDA), gave an overview of what the FDA is doing to help strike innovative T1D products Sir Thomas More quickly to those who seat gain from them. From JDRF's own work to fund research and shape the regulatory pathway for artificial pancreas systems, we roll in the hay the Food and Drug Administration is playacting a leaders role to advance innovative T1D products. Dr. Lias same the FDA's Center for Devices and Radiological Health is seeking to enforce principles from the CRDH Design Pathway as it plant with innovators underdeveloped a variety of products.

* Howard Look gave a very passionate talk on the exchange of T1D information. As the parent of a child with T1D, his vocalization was loud and crystallize on the need to "localize the information free." Mr. Look created Tidepool, an open source, open platform, cloud-founded data direction tool that helps individuals with T1D capture their daily T1D management activities. Using apps like Blip and Nutshell can help make diabetes self-care more visualized, informative and effective. Concurrently, one of the biggest frustrations among users is that these tools and devices don't talk to apiece other. Users must use a separate tool to consolidate the data from different devices and get by their diabetes. We often hear that companies don't support the unselfish of this data because their platforms are "patented." Even so, Mr. Look made the point that the data comes from patients, and should therefore belong to patients as well.

* Continuing the theme of a patient-centric set about, JDRF powerfully agrees with the comments definite at the Summit by patient advocate Anna McCollister-Slipp WHO troubled that spell FDA, industry, and payers are all important stakeholders in the innovation of T1D products, patients should glucinium the ones taking the leave. Patients have to sound off and let all the stakeholders know what is right for them.

* A Forbearing Voices Survey presented by Amy Tenderich and some of the diligent winners provided deep insights into the daily issues and challenges that fundamental stakeholders need to tackle in order to really help those affected by T1D. If anyone wants to develop an innovative and truly beneficial diabetes like cartesian product, I would highly recommend reading this survey. JDRF uses a variety of approaches, including our T1D Voices Council, to collect perspectives on the needs of those with and affected by this disease, and we congratulate others finding new-sprung ways to amplify the voices of the most important stakeholder — individuals with T1D.

I heard about omnipotent messages from individuals with T1D at the Summit this twelvemonth. The plebeian theme of using technology to enable a better life really strike home for me. The very vocalise the great unwashe who spoke hit the key aspects of what meaningful innovation means to them for T1D, including: human-centered, unlobed, convenient, introjected, and accurate.

Those of us on the JDRF Unreal Pancreas team have been functional herculean to drive meaningful technology instauratio towards our net goal, fully automatic artificial pancreas systems, because we know from people with T1D that such systems would revolutionise the management of this disease. We're resolute to give them what they really want, and I left the Summit impelled by the patient voices I heard to redouble our efforts to deliver life-ever-changing technologies to those who so desperately need them.

On a separate but attendant note, I wanted to share with you an exciting announcement that JDRF made freshly about moving innovative T1D products closer to patients. We just announced the launch of a novel adventure-creating entity called T1D Innovations to accelerate the ontogenesis of innovative T1D therapies and devices. T1D Innovations leave make up and fund altissimo-impact companies to translate key discoveries into novel T1D products, sanctioning them to cross the known biomedical "valley of death" — the notorious translational gap that oft prevents promising biomedical discoveries from being developed and reaching patients. This is another example of JDRF's focus on determination innovative ways to give individuals with T1D a better spirit on our journeying to a curative.

Thanks to Amy Tenderich for organizing this fantastic consequence, sol all of US have an opportunity to hear from those who give the biggest stake in the outcomes of our combined efforts — individuals with T1D and their adored ones.